Yongfeng Wu

950 total citations
13 papers, 558 citations indexed

About

Yongfeng Wu is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Yongfeng Wu has authored 13 papers receiving a total of 558 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Yongfeng Wu's work include Cancer Immunotherapy and Biomarkers (3 papers), RNA modifications and cancer (3 papers) and Cancer-related molecular mechanisms research (3 papers). Yongfeng Wu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (3 papers), RNA modifications and cancer (3 papers) and Cancer-related molecular mechanisms research (3 papers). Yongfeng Wu collaborates with scholars based in China, United States and Singapore. Yongfeng Wu's co-authors include Dajing Xia, Yihua Wu, Yuequn Niu, Honghe Zhang, Jian Hu, Wenjie Sun, Wei Lu, Han Wu, Han‐Ming Shen and Hongyi Li and has published in prestigious journals such as Oncogene, Frontiers in Immunology and Molecular Cancer.

In The Last Decade

Yongfeng Wu

13 papers receiving 555 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yongfeng Wu China 10 370 293 181 92 67 13 558
Deyuan Fu China 14 359 1.0× 326 1.1× 168 0.9× 101 1.1× 45 0.7× 35 614
Taichi Isobe Japan 12 325 0.9× 209 0.7× 186 1.0× 51 0.6× 57 0.9× 34 490
Anup Sharma United States 12 495 1.3× 159 0.5× 237 1.3× 72 0.8× 73 1.1× 23 668
Dian-na Gu China 12 306 0.8× 282 1.0× 151 0.8× 72 0.8× 70 1.0× 27 516
Courtney A. Bartel United States 11 286 0.8× 135 0.5× 199 1.1× 92 1.0× 75 1.1× 13 481
Chie Soeno Japan 10 326 0.9× 211 0.7× 124 0.7× 104 1.1× 31 0.5× 13 454
Xiangli Jiang China 14 307 0.8× 222 0.8× 171 0.9× 171 1.9× 45 0.7× 23 512
Jue‐Yu Zhou China 15 426 1.2× 278 0.9× 110 0.6× 54 0.6× 42 0.6× 42 591
Maria Cardenas United States 6 266 0.7× 198 0.7× 214 1.2× 117 1.3× 46 0.7× 14 496
Na Zhou China 14 266 0.7× 223 0.8× 156 0.9× 55 0.6× 99 1.5× 33 488

Countries citing papers authored by Yongfeng Wu

Since Specialization
Citations

This map shows the geographic impact of Yongfeng Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yongfeng Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yongfeng Wu more than expected).

Fields of papers citing papers by Yongfeng Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yongfeng Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yongfeng Wu. The network helps show where Yongfeng Wu may publish in the future.

Co-authorship network of co-authors of Yongfeng Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Yongfeng Wu. A scholar is included among the top collaborators of Yongfeng Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yongfeng Wu. Yongfeng Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Yang, Dexin, Yuequn Niu, Jing Leng, et al.. (2022). Identification of metastasis-related long non-coding RNAs in lung cancer through a novel tumor mesenchymal score. Pathology - Research and Practice. 237. 154018–154018. 3 indexed citations
2.
Xu, Jiawei, et al.. (2022). Safety of Neoadjuvant Immunotherapy in Resectable Cancers: A Meta-Analysis. Frontiers in Immunology. 13. 802672–802672. 4 indexed citations
3.
Wu, Yongfeng, Dexin Yang, Yuequn Niu, et al.. (2021). Driver and novel genes correlated with metastasis of non-small cell lung cancer: A comprehensive analysis. Pathology - Research and Practice. 224. 153551–153551. 17 indexed citations
4.
Wu, Yongfeng, Jiawei Xu, Yiqing Wang, et al.. (2020). The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age. Biomarker Research. 8(1). 9–9. 22 indexed citations
5.
Xu, Jiawei, Kelie Chen, Fan Zhao, et al.. (2020). Association between vitamin D/calcium intake and 25-hydroxyvitamin D and risk of ovarian cancer: a dose-response relationship meta-analysis. European Journal of Clinical Nutrition. 75(3). 417–429. 13 indexed citations
6.
Wu, Yongfeng, Yuequn Niu, Jing Leng, et al.. (2019). Benzo(a)pyrene regulated A549 cell migration, invasion and epithelial-mesenchymal transition by up-regulating long non-coding RNA linc00673. Toxicology Letters. 320. 37–45. 27 indexed citations
7.
Wu, Yongfeng, Jinming Xu, Chengli Du, et al.. (2019). The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis. Frontiers in Oncology. 9. 1161–1161. 102 indexed citations
8.
Manegold, Philipp, Keane K. Y. Lai, Yongfeng Wu, et al.. (2018). Differentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic Cancer. Cancers. 10(4). 95–95. 43 indexed citations
9.
Li, Jun, et al.. (2018). Upregulation of RECQL4 expression predicts poor prognosis in hepatocellular carcinoma. Oncology Letters. 15(4). 4248–4254. 20 indexed citations
10.
Zhao, Yi, et al.. (2018). Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists. Current Molecular Pharmacology. 11(2). 113–121. 10 indexed citations
11.
Lu, Wei, Honghe Zhang, Yuequn Niu, et al.. (2017). Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p. Molecular Cancer. 16(1). 118–118. 253 indexed citations
12.
Zhao, Yi, David Masiello, Michael McMillian, et al.. (2015). CBP/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells. Oncogene. 35(28). 3705–3717. 43 indexed citations
13.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Deyuan Fu Breakdown of academic impact, for papers by Taichi Isobe Breakdown of academic impact, for papers by Anup Sharma Breakdown of academic impact, for papers by Dian-na Gu Breakdown of academic impact, for papers by Courtney A. Bartel Breakdown of academic impact, for papers by Chie Soeno Breakdown of academic impact, for papers by Xiangli Jiang Breakdown of academic impact, for papers by Jue‐Yu Zhou Breakdown of academic impact, for papers by Maria Cardenas Breakdown of academic impact, for papers by Na Zhou
Rankless by CCL
2026